Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965812 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL12222340 | 0.82 | GRM4 (0.54) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL15965810 | 0.79 | PIK3CA (0.51) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL11398989 | 0.77 | CA12 (0.62) | CA12CA1CA2CA9PDE10A | |
| SCHEMBL11394107 | 0.77 | CA12 (0.62) | CA12CA1CA2CA9PDE10A | |
| SCHEMBL31227531 | 0.76 | CA12 (0.45) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL6799337 | 0.76 | LMNA (0.63) | CA12CA1CA2CA9PDE10A | |
| SCHEMBL6798812 | 0.76 | NPC1 (0.63) | CA12CA1CA2CA9GRM4 | |
| SCHEMBL15954728 | 0.76 | MAPT (0.55) | LMNANPC1HTT | |
| SCHEMBL15953619 | 0.76 | CA12 (0.47) | CA12CA1CA2CA9PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2014128585-A1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322065-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | CA12 359/4885CA1 2741/4885CA2 1048/4885 |
| US-20140235612-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | CA12 359/4885CA1 2741/4885CA2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.